Actively Recruiting
Evaluating Oral N-Acetylcysteine With Supportive Care Versus Supportive Care Alone in Adults With Non-Acetaminophen Acute Liver Failure
Led by King Edward Medical University · Updated on 2026-08-19
62
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding oral N-acetylcysteine NAC to standard supportive care improves survival and reduces mortality in adults aged 18 to 60 with non-acetaminophen-induced acute liver failure ALF. This trial is conducted in a setting where liver transplant is often not accessible, focusing on the potential benefits of NAC in a critical liver condition with high mortality. The study is randomized and controlled to compare NAC plus supportive care against supportive care alone. Participants assigned to the NAC group will receive oral or nasogastric NAC at a dose of 140 mgkg every 4 hours for the first 16 hours, then every 6 to 8 hours, for a total of 3 days, alongside standard supportive care. The control group will receive standard supportive care only, which includes glucose monitoring, antimicrobials, proton pump inhibitors, fluid and electrolyte management, measures against encephalopathy, and fresh frozen plasma if needed. The treatment period lasts for 3 days with follow-up until 28 days. During the study, participants will be monitored for survival and mortality at 28 days after enrollment. Researchers will also assess the length of hospital stay and improvements in liver function tests by day 4. The trial uses randomization to assign 62 adult patients evenly between the two groups. Safety and outcomes will be closely observed over the 28-day period following treatment initiation.
CONDITIONS
Brief Title
Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure
Research Team
S
Somia Iqtadar, FCPS
Z
Zaeem Ahmad, MBBS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here